nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—amyotrophic lateral sclerosis	0.501	1	CbGaD
Lenalidomide—TNFSF11—jaw skeleton—amyotrophic lateral sclerosis	0.0439	0.245	CbGeAlD
Lenalidomide—TNFSF11—forelimb—amyotrophic lateral sclerosis	0.0262	0.147	CbGeAlD
Lenalidomide—TNFSF11—hindlimb—amyotrophic lateral sclerosis	0.0236	0.132	CbGeAlD
Lenalidomide—TNFSF11—appendage—amyotrophic lateral sclerosis	0.0202	0.113	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—CNTF—amyotrophic lateral sclerosis	0.0198	0.284	CbGpPWpGaD
Lenalidomide—TNFSF11—tongue—amyotrophic lateral sclerosis	0.014	0.0784	CbGeAlD
Lenalidomide—CDH5—Cell-cell junction organization—MPP5—amyotrophic lateral sclerosis	0.00951	0.137	CbGpPWpGaD
Lenalidomide—Subarachnoid haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00749	0.0303	CcSEcCtD
Lenalidomide—CDH5—Cell junction organization—MPP5—amyotrophic lateral sclerosis	0.00719	0.103	CbGpPWpGaD
Lenalidomide—TNFSF11—embryo—amyotrophic lateral sclerosis	0.00672	0.0376	CbGeAlD
Lenalidomide—Alveolitis allergic—Riluzole—amyotrophic lateral sclerosis	0.00627	0.0253	CcSEcCtD
Lenalidomide—CDH5—Cell-Cell communication—MPP5—amyotrophic lateral sclerosis	0.00512	0.0736	CbGpPWpGaD
Lenalidomide—CDH5—embryo—amyotrophic lateral sclerosis	0.00505	0.0283	CbGeAlD
Lenalidomide—Gastrointestinal tract irritation—Riluzole—amyotrophic lateral sclerosis	0.00458	0.0185	CcSEcCtD
Lenalidomide—Stiffness—Riluzole—amyotrophic lateral sclerosis	0.0043	0.0174	CcSEcCtD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—SQSTM1—amyotrophic lateral sclerosis	0.00384	0.0552	CbGpPWpGaD
Lenalidomide—Cerebral ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00338	0.0137	CcSEcCtD
Lenalidomide—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00333	0.0135	CcSEcCtD
Lenalidomide—Muscle relaxant therapy—Riluzole—amyotrophic lateral sclerosis	0.00329	0.0133	CcSEcCtD
Lenalidomide—CDH5—medulla oblongata—amyotrophic lateral sclerosis	0.00323	0.0181	CbGeAlD
Lenalidomide—CRBN—embryo—amyotrophic lateral sclerosis	0.00321	0.018	CbGeAlD
Lenalidomide—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.0032	0.0129	CcSEcCtD
Lenalidomide—Hypotonia—Riluzole—amyotrophic lateral sclerosis	0.00311	0.0126	CcSEcCtD
Lenalidomide—PTGS2—hindlimb—amyotrophic lateral sclerosis	0.00307	0.0172	CbGeAlD
Lenalidomide—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00292	0.0118	CcSEcCtD
Lenalidomide—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00288	0.0116	CcSEcCtD
Lenalidomide—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00288	0.0116	CcSEcCtD
Lenalidomide—CDH5—spinal cord—amyotrophic lateral sclerosis	0.00288	0.0161	CbGeAlD
Lenalidomide—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00285	0.0115	CcSEcCtD
Lenalidomide—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00269	0.0109	CcSEcCtD
Lenalidomide—PTGS2—appendage—amyotrophic lateral sclerosis	0.00263	0.0147	CbGeAlD
Lenalidomide—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.00257	0.0104	CcSEcCtD
Lenalidomide—Hypoxia—Riluzole—amyotrophic lateral sclerosis	0.00257	0.0104	CcSEcCtD
Lenalidomide—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00257	0.0104	CcSEcCtD
Lenalidomide—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00255	0.0103	CcSEcCtD
Lenalidomide—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0025	0.0101	CcSEcCtD
Lenalidomide—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.0025	0.0101	CcSEcCtD
Lenalidomide—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00245	0.00988	CcSEcCtD
Lenalidomide—CDH5—nervous system—amyotrophic lateral sclerosis	0.00243	0.0136	CbGeAlD
Lenalidomide—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00238	0.0096	CcSEcCtD
Lenalidomide—CDH5—central nervous system—amyotrophic lateral sclerosis	0.00234	0.0131	CbGeAlD
Lenalidomide—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00934	CcSEcCtD
Lenalidomide—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00934	CcSEcCtD
Lenalidomide—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00925	CcSEcCtD
Lenalidomide—CDH5—cerebellum—amyotrophic lateral sclerosis	0.00228	0.0128	CbGeAlD
Lenalidomide—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00219	0.00885	CcSEcCtD
Lenalidomide—Pomalidomide—PTGS2—amyotrophic lateral sclerosis	0.00214	0.608	CrCbGaD
Lenalidomide—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00863	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—IGF1—amyotrophic lateral sclerosis	0.00209	0.0301	CbGpPWpGaD
Lenalidomide—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00207	0.00835	CcSEcCtD
Lenalidomide—CRBN—medulla oblongata—amyotrophic lateral sclerosis	0.00205	0.0115	CbGeAlD
Lenalidomide—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00822	CcSEcCtD
Lenalidomide—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00816	CcSEcCtD
Lenalidomide—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00803	CcSEcCtD
Lenalidomide—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00797	CcSEcCtD
Lenalidomide—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.00186	0.00752	CcSEcCtD
Lenalidomide—CDH5—brain—amyotrophic lateral sclerosis	0.00185	0.0104	CbGeAlD
Lenalidomide—CRBN—spinal cord—amyotrophic lateral sclerosis	0.00183	0.0102	CbGeAlD
Lenalidomide—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00737	CcSEcCtD
Lenalidomide—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00732	CcSEcCtD
Lenalidomide—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00727	CcSEcCtD
Lenalidomide—Gout—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00708	CcSEcCtD
Lenalidomide—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00699	CcSEcCtD
Lenalidomide—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00699	CcSEcCtD
Lenalidomide—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00173	0.00699	CcSEcCtD
Lenalidomide—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00694	CcSEcCtD
Lenalidomide—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00677	CcSEcCtD
Lenalidomide—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00673	CcSEcCtD
Lenalidomide—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00166	0.00669	CcSEcCtD
Lenalidomide—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00661	CcSEcCtD
Lenalidomide—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00661	CcSEcCtD
Lenalidomide—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00162	0.00653	CcSEcCtD
Lenalidomide—Melaena—Riluzole—amyotrophic lateral sclerosis	0.0016	0.00645	CcSEcCtD
Lenalidomide—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00638	CcSEcCtD
Lenalidomide—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00638	CcSEcCtD
Lenalidomide—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00631	CcSEcCtD
Lenalidomide—CRBN—nervous system—amyotrophic lateral sclerosis	0.00154	0.00862	CbGeAlD
Lenalidomide—CRBN—central nervous system—amyotrophic lateral sclerosis	0.00148	0.0083	CbGeAlD
Lenalidomide—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00597	CcSEcCtD
Lenalidomide—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00597	CcSEcCtD
Lenalidomide—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00588	CcSEcCtD
Lenalidomide—CRBN—cerebellum—amyotrophic lateral sclerosis	0.00145	0.00811	CbGeAlD
Lenalidomide—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00573	CcSEcCtD
Lenalidomide—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00562	CcSEcCtD
Lenalidomide—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00562	CcSEcCtD
Lenalidomide—Thalidomide—PTGS2—amyotrophic lateral sclerosis	0.00138	0.392	CrCbGaD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—amyotrophic lateral sclerosis	0.00137	0.0196	CbGpPWpGaD
Lenalidomide—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00551	CcSEcCtD
Lenalidomide—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00536	CcSEcCtD
Lenalidomide—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00534	CcSEcCtD
Lenalidomide—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00529	CcSEcCtD
Lenalidomide—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00506	CcSEcCtD
Lenalidomide—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00493	CcSEcCtD
Lenalidomide—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00491	CcSEcCtD
Lenalidomide—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00482	CcSEcCtD
Lenalidomide—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.0048	CcSEcCtD
Lenalidomide—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00119	0.0048	CcSEcCtD
Lenalidomide—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00119	0.0048	CcSEcCtD
Lenalidomide—CRBN—brain—amyotrophic lateral sclerosis	0.00118	0.00659	CbGeAlD
Lenalidomide—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00472	CcSEcCtD
Lenalidomide—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00472	CcSEcCtD
Lenalidomide—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00463	CcSEcCtD
Lenalidomide—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00456	CcSEcCtD
Lenalidomide—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00456	CcSEcCtD
Lenalidomide—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00454	CcSEcCtD
Lenalidomide—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00451	CcSEcCtD
Lenalidomide—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00446	CcSEcCtD
Lenalidomide—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00443	CcSEcCtD
Lenalidomide—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00437	CcSEcCtD
Lenalidomide—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00433	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00432	CcSEcCtD
Lenalidomide—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00424	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00423	CcSEcCtD
Lenalidomide—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00423	CcSEcCtD
Lenalidomide—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00417	CcSEcCtD
Lenalidomide—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00415	CcSEcCtD
Lenalidomide—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00415	CcSEcCtD
Lenalidomide—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00415	CcSEcCtD
Lenalidomide—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00406	CcSEcCtD
Lenalidomide—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.000999	0.00404	CcSEcCtD
Lenalidomide—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.000987	0.00399	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—PTPRZ1—amyotrophic lateral sclerosis	0.000985	0.0142	CbGpPWpGaD
Lenalidomide—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000984	0.00397	CcSEcCtD
Lenalidomide—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.000974	0.00394	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—RAB5A—amyotrophic lateral sclerosis	0.000964	0.0139	CbGpPWpGaD
Lenalidomide—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.000959	0.00388	CcSEcCtD
Lenalidomide—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.000959	0.00388	CcSEcCtD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—TPK1—amyotrophic lateral sclerosis	0.000953	0.0137	CbGpPWpGaD
Lenalidomide—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.000948	0.00383	CcSEcCtD
Lenalidomide—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.000945	0.00382	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000937	0.00378	CcSEcCtD
Lenalidomide—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000934	0.00377	CcSEcCtD
Lenalidomide—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000928	0.00375	CcSEcCtD
Lenalidomide—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00092	0.00372	CcSEcCtD
Lenalidomide—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.000915	0.0037	CcSEcCtD
Lenalidomide—Infestation—Riluzole—amyotrophic lateral sclerosis	0.000915	0.0037	CcSEcCtD
Lenalidomide—Depression—Riluzole—amyotrophic lateral sclerosis	0.000912	0.00369	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.000902	0.00364	CcSEcCtD
Lenalidomide—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.000897	0.00362	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000897	0.00362	CcSEcCtD
Lenalidomide—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000892	0.0036	CcSEcCtD
Lenalidomide—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.000889	0.00359	CcSEcCtD
Lenalidomide—Sweating—Riluzole—amyotrophic lateral sclerosis	0.000877	0.00354	CcSEcCtD
Lenalidomide—PTGS2—embryo—amyotrophic lateral sclerosis	0.000874	0.00489	CbGeAlD
Lenalidomide—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.000872	0.00352	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.000865	0.0035	CcSEcCtD
Lenalidomide—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000863	0.00349	CcSEcCtD
Lenalidomide—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.000858	0.00347	CcSEcCtD
Lenalidomide—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000854	0.00345	CcSEcCtD
Lenalidomide—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000836	0.00338	CcSEcCtD
Lenalidomide—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000825	0.00333	CcSEcCtD
Lenalidomide—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000823	0.00333	CcSEcCtD
Lenalidomide—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000821	0.00332	CcSEcCtD
Lenalidomide—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000821	0.00332	CcSEcCtD
Lenalidomide—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000817	0.0033	CcSEcCtD
Lenalidomide—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.000817	0.0033	CcSEcCtD
Lenalidomide—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000815	0.00329	CcSEcCtD
Lenalidomide—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000811	0.00328	CcSEcCtD
Lenalidomide—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000809	0.00327	CcSEcCtD
Lenalidomide—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000807	0.00326	CcSEcCtD
Lenalidomide—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000805	0.00325	CcSEcCtD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—amyotrophic lateral sclerosis	0.000783	0.0113	CbGpPWpGaD
Lenalidomide—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000777	0.00314	CcSEcCtD
Lenalidomide—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000768	0.0031	CcSEcCtD
Lenalidomide—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000762	0.00308	CcSEcCtD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000752	0.0108	CbGpPWpGaD
Lenalidomide—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000745	0.00301	CcSEcCtD
Lenalidomide—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000742	0.003	CcSEcCtD
Lenalidomide—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00074	0.00299	CcSEcCtD
Lenalidomide—Chills—Riluzole—amyotrophic lateral sclerosis	0.000737	0.00298	CcSEcCtD
Lenalidomide—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000734	0.00296	CcSEcCtD
Lenalidomide—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000726	0.00293	CcSEcCtD
Lenalidomide—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00072	0.00291	CcSEcCtD
Lenalidomide—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000715	0.00289	CcSEcCtD
Lenalidomide—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000704	0.00285	CcSEcCtD
Lenalidomide—Tension—Riluzole—amyotrophic lateral sclerosis	0.000702	0.00283	CcSEcCtD
Lenalidomide—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00283	CcSEcCtD
Lenalidomide—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000694	0.00281	CcSEcCtD
Lenalidomide—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000692	0.00279	CcSEcCtD
Lenalidomide—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000687	0.00278	CcSEcCtD
Lenalidomide—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00067	0.00271	CcSEcCtD
Lenalidomide—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000663	0.00268	CcSEcCtD
Lenalidomide—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000661	0.00267	CcSEcCtD
Lenalidomide—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000657	0.00265	CcSEcCtD
Lenalidomide—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000653	0.00264	CcSEcCtD
Lenalidomide—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000645	0.0026	CcSEcCtD
Lenalidomide—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000642	0.0026	CcSEcCtD
Lenalidomide—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000641	0.00259	CcSEcCtD
Lenalidomide—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00064	0.00259	CcSEcCtD
Lenalidomide—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000632	0.00255	CcSEcCtD
Lenalidomide—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000628	0.00254	CcSEcCtD
Lenalidomide—Cough—Riluzole—amyotrophic lateral sclerosis	0.000624	0.00252	CcSEcCtD
Lenalidomide—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000617	0.00249	CcSEcCtD
Lenalidomide—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000609	0.00246	CcSEcCtD
Lenalidomide—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000609	0.00246	CcSEcCtD
Lenalidomide—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000609	0.00246	CcSEcCtD
Lenalidomide—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000607	0.00245	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000604	0.00244	CcSEcCtD
Lenalidomide—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000601	0.00243	CcSEcCtD
Lenalidomide—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000595	0.0024	CcSEcCtD
Lenalidomide—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000588	0.00238	CcSEcCtD
Lenalidomide—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000583	0.00236	CcSEcCtD
Lenalidomide—Infection—Riluzole—amyotrophic lateral sclerosis	0.00058	0.00234	CcSEcCtD
Lenalidomide—Shock—Riluzole—amyotrophic lateral sclerosis	0.000574	0.00232	CcSEcCtD
Lenalidomide—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000572	0.00231	CcSEcCtD
Lenalidomide—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000571	0.00231	CcSEcCtD
Lenalidomide—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000569	0.0023	CcSEcCtD
Lenalidomide—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000567	0.00229	CcSEcCtD
Lenalidomide—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000564	0.00228	CcSEcCtD
Lenalidomide—PTGS2—medulla oblongata—amyotrophic lateral sclerosis	0.000559	0.00312	CbGeAlD
Lenalidomide—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000556	0.00225	CcSEcCtD
Lenalidomide—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000545	0.0022	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—amyotrophic lateral sclerosis	0.000545	0.00783	CbGpPWpGaD
Lenalidomide—ABCB1—embryo—amyotrophic lateral sclerosis	0.000541	0.00302	CbGeAlD
Lenalidomide—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000532	0.00215	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—amyotrophic lateral sclerosis	0.000528	0.00759	CbGpPWpGaD
Lenalidomide—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000528	0.00213	CcSEcCtD
Lenalidomide—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000524	0.00212	CcSEcCtD
Lenalidomide—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00052	0.0021	CcSEcCtD
Lenalidomide—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000519	0.0021	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—amyotrophic lateral sclerosis	0.000515	0.0074	CbGpPWpGaD
Lenalidomide—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000514	0.00208	CcSEcCtD
Lenalidomide—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000507	0.00205	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000504	0.00204	CcSEcCtD
Lenalidomide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000503	0.00203	CcSEcCtD
Lenalidomide—Pain—Riluzole—amyotrophic lateral sclerosis	0.000499	0.00202	CcSEcCtD
Lenalidomide—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000499	0.00202	CcSEcCtD
Lenalidomide—PTGS2—spinal cord—amyotrophic lateral sclerosis	0.000498	0.00279	CbGeAlD
Lenalidomide—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000481	0.00194	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.000477	0.00686	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000477	0.00193	CcSEcCtD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—amyotrophic lateral sclerosis	0.000471	0.00676	CbGpPWpGaD
Lenalidomide—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000464	0.00187	CcSEcCtD
Lenalidomide—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000461	0.00186	CcSEcCtD
Lenalidomide—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000461	0.00186	CcSEcCtD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.000458	0.00658	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00043	0.00174	CcSEcCtD
Lenalidomide—PTGS2—nervous system—amyotrophic lateral sclerosis	0.00042	0.00235	CbGeAlD
Lenalidomide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000419	0.00169	CcSEcCtD
Lenalidomide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000413	0.00167	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—PLA2G4A—amyotrophic lateral sclerosis	0.000405	0.00582	CbGpPWpGaD
Lenalidomide—PTGS2—central nervous system—amyotrophic lateral sclerosis	0.000404	0.00226	CbGeAlD
Lenalidomide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000399	0.00161	CcSEcCtD
Lenalidomide—PTGS2—cerebellum—amyotrophic lateral sclerosis	0.000395	0.00221	CbGeAlD
Lenalidomide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000386	0.00156	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—RTN4—amyotrophic lateral sclerosis	0.000385	0.00553	CbGpPWpGaD
Lenalidomide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000371	0.0015	CcSEcCtD
Lenalidomide—Rash—Riluzole—amyotrophic lateral sclerosis	0.000368	0.00149	CcSEcCtD
Lenalidomide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000368	0.00148	CcSEcCtD
Lenalidomide—Headache—Riluzole—amyotrophic lateral sclerosis	0.000366	0.00148	CcSEcCtD
Lenalidomide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000347	0.0014	CcSEcCtD
Lenalidomide—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000345	0.00193	CbGeAlD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—amyotrophic lateral sclerosis	0.000336	0.00483	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000327	0.0047	CbGpPWpGaD
Lenalidomide—PTGS2—brain—amyotrophic lateral sclerosis	0.000321	0.00179	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000321	0.00461	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—GFAP—amyotrophic lateral sclerosis	0.000314	0.00451	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	0.00031	0.00446	CbGpPWpGaD
Lenalidomide—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000308	0.00172	CbGeAlD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—amyotrophic lateral sclerosis	0.000304	0.00437	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000304	0.00437	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000302	0.00433	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—amyotrophic lateral sclerosis	0.000293	0.00421	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000286	0.00411	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000277	0.00398	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000267	0.00383	CbGpPWpGaD
Lenalidomide—ABCB1—nervous system—amyotrophic lateral sclerosis	0.00026	0.00145	CbGeAlD
Lenalidomide—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.00025	0.0014	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000246	0.00353	CbGpPWpGaD
Lenalidomide—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000244	0.00137	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000243	0.00349	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000232	0.00333	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000216	0.0031	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000212	0.00305	CbGpPWpGaD
Lenalidomide—ABCB1—brain—amyotrophic lateral sclerosis	0.000198	0.00111	CbGeAlD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000194	0.00279	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000189	0.00272	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.000186	0.00267	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000183	0.00264	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00018	0.00259	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000178	0.00256	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.00017	0.00244	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000168	0.00241	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000167	0.0024	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	0.00016	0.00231	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.000159	0.00229	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000157	0.00225	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.00015	0.00215	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000149	0.00214	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000144	0.00208	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	0.000136	0.00195	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000132	0.0019	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.00013	0.00187	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000129	0.00186	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000128	0.00184	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000126	0.00181	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.00012	0.00173	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000119	0.00171	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000116	0.00167	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TPK1—amyotrophic lateral sclerosis	0.000113	0.00162	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000109	0.00157	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000108	0.00156	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000106	0.00153	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000104	0.0015	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.88e-05	0.00142	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	9.44e-05	0.00136	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	9.44e-05	0.00136	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	9.17e-05	0.00132	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	9.02e-05	0.0013	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	8.81e-05	0.00127	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	8.64e-05	0.00124	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.16e-05	0.00117	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.03e-05	0.00115	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	8.01e-05	0.00115	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	7.83e-05	0.00113	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	7.73e-05	0.00111	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	7.67e-05	0.0011	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	7.57e-05	0.00109	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	7.55e-05	0.00109	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	7.38e-05	0.00106	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	7.08e-05	0.00102	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	6.98e-05	0.001	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	6.83e-05	0.000982	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	6.83e-05	0.000981	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	6.7e-05	0.000962	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	6.7e-05	0.000962	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	6.64e-05	0.000955	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.28e-05	0.000903	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	6.18e-05	0.000888	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	6.12e-05	0.00088	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.94e-05	0.000853	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	5.94e-05	0.000853	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	5.94e-05	0.000853	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.69e-05	0.000818	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	5.51e-05	0.000792	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	5.45e-05	0.000783	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.35e-05	0.000769	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.33e-05	0.000766	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	5.29e-05	0.00076	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	5.17e-05	0.000744	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	5.14e-05	0.000738	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	5.02e-05	0.000722	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	4.84e-05	0.000696	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	4.78e-05	0.000686	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	4.63e-05	0.000665	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	4.35e-05	0.000625	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	4.16e-05	0.000598	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.03e-05	0.000579	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	3.95e-05	0.000568	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	3.92e-05	0.000564	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.86e-05	0.000555	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.67e-05	0.000527	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.58e-05	0.000514	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.49e-05	0.000502	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	3.39e-05	0.000487	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	3.28e-05	0.000471	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	2.87e-05	0.000413	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.78e-05	0.0004	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.48e-05	0.000356	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	2.46e-05	0.000354	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.11e-05	0.000303	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.94e-05	0.000278	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	1.9e-05	0.000274	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	1.59e-05	0.000229	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.49e-05	0.000215	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.37e-05	0.000197	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	1.13e-05	0.000162	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.74e-06	0.000111	CbGpPWpGaD
